{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:40:20Z","timestamp":1788910820354,"version":"build-2803163510"},"reference-count":43,"publisher":"Walter de Gruyter GmbH","issue":"4","funder":[{"DOI":"10.13039\/100008882","name":"Texas State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_hmbci-2021-0011_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Visfatin is found in adipose tissue and is referred to as nicotinamide phosphoribosyltransferase (Nampt). Visfatin has anti-apoptotic, proliferative, and metastatic properties and may mediate its effects via ERK and PI3K\/Akt signaling. Studies have yet to determine whether inhibition of kinase signaling will suppress visfatin-induced liver cancer. The purpose of this study was to determine which signaling pathways visfatin may promote liver cancer progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0011_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HepG2 and SNU-449 liver cancer cells were exposed to visfatin with or without ERK or PI3K\/Akt inhibitor, or both inhibitors combined. These processes that were assessed: proliferation, reactive oxygen species (ROS), lipogenesis, invasion, and matrix metalloproteinase (MMP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0011_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Inhibition of PI3K\/Akt and combination of inhibitors suppressed visfatin-induced viability. ERK inhibition in HepG2 cells decreased visfatin-induced proliferation. ERK inhibitor alone or in combination with PI3K inhibitors effectively suppressed MMP-9 secretion and invasion in liver cancer cells. PI3K and ERK inhibition and PI3K inhibition alone blocked visfatin\u2019s ROS production in SNU-449\u00a0cells. These results corresponded with a decrease in phosphorylated Akt and ERK, \u03b2-catenin, and fatty acid synthase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_hmbci-2021-0011_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Akt and ERK inhibition differentially regulated physiological changes in liver cancer cells. Inhibition of Akt and ERK signaling pathways suppressed visfatin-induced invasion, viability, MMP-9 activation, and ROS production.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/hmbci-2021-0011","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T10:46:42Z","timestamp":1630061202000},"page":"357-366","source":"Crossref","is-referenced-by-count":10,"title":["Inhibition of PI3K\/Akt and ERK signaling decreases visfatin-induced invasion in liver cancer cells"],"prefix":"10.1515","volume":"42","author":[{"given":"Candace","family":"Miethe","sequence":"first","affiliation":[{"name":"Nutrition and Foods , Texas State University , San Marcos , TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Torres","sequence":"additional","affiliation":[{"name":"Psychology , Texas State University , San Marcos , TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Zamora","sequence":"additional","affiliation":[{"name":"Nutrition and Foods , Texas State University , San Marcos , TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona S.","family":"Price","sequence":"additional","affiliation":[{"name":"Nutrition and Foods , Texas State University , San Marcos , TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"2025121207243546721_j_hmbci-2021-0011_ref_001","unstructured":"The American Cancer Society. About liver cancer. Available from: https:\/\/www.cancer.org\/cancer\/liver-cancer\/about.html [Accessed 22 Jul 2020]."},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_002","unstructured":"CDC. Adult obesity facts. Available from: https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db360.htm [Accessed 15 May 2020]."},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_003","doi-asserted-by":"crossref","unstructured":"Ninomiya, S, Shimizu, M, Imai, K, Takai, K, Shiraki, M, Hara, T, et al. Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells. Canc Prev Res 2011;4:2092\u2013100. https:\/\/doi.org\/10.1158\/1940-6207.capr-11-0340.","DOI":"10.1158\/1940-6207.CAPR-11-0340"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_004","doi-asserted-by":"crossref","unstructured":"Saddi-Rosa, P, Oliveira, CS, Giuffrida, FM, Reis, AF. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndrome 2010;2:21. https:\/\/doi.org\/10.1186\/1758-5996-2-21.","DOI":"10.1186\/1758-5996-2-21"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_005","doi-asserted-by":"crossref","unstructured":"Zahorska-Markiewicz, B, Olszanecka-Glinianowicz, M, Janowska, J, Koce\u0142ak, P, Semik-Grabarczyk, E, Holecki, M, et al. Serum concentration of visfatin in obese women. Metabolism 2007;56:1131\u20134. https:\/\/doi.org\/10.1016\/j.metabol.2007.04.007.","DOI":"10.1016\/j.metabol.2007.04.007"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_006","doi-asserted-by":"crossref","unstructured":"Gholinejad, Z, Kheiripour, N, Nourbakhsh, M, Ilbeigi, D, Heasan, Z, Golestani, A, et al. Extracellular NAMPT\/visfatin induces proliferation through ERK1\/2 and AKT and inhibits apoptosis in breast cancer cells. Pept Int J 2017;92:9\u201315. https:\/\/doi.org\/10.1016\/j.peptides.2017.04.007.","DOI":"10.1016\/j.peptides.2017.04.007"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_007","doi-asserted-by":"crossref","unstructured":"Panahi, G, Pasalar, P, Zare, M, Rizzuto, R, Meshkari, R. High glucose induces inflammatory responses in HepG2 cells via the oxidative stress-mediated activation of NF-\u03baB, and MAPK pathways in HepG2 cells. Arch Physiol Biochem 2018;124:468\u201374. https:\/\/doi.org\/10.1080\/13813455.2018.1427764.","DOI":"10.1080\/13813455.2018.1427764"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_008","doi-asserted-by":"crossref","unstructured":"Muranen, T, Sefoprs, LM, Hwang, J, Gallegos, LL, Coloff, JL, Thoreen, CC, et al. ERK and p38 MAPK activities determine sensitivity to PI3K\/mTOR inhibition via regulation of MYC and YAP. Canc Res 2016;76:7168\u201380. https:\/\/doi.org\/10.1158\/0008-5472.can-16-0155.","DOI":"10.1158\/0008-5472.CAN-16-0155"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_009","doi-asserted-by":"crossref","unstructured":"Cao, X, Xu, L, Lin, Q, Yang, L, Li, N, Li, X, et al. MicroRNA-1277 inhibits proliferation and migration of hepatocellular carcinoma HepG2 cells by targeting and suppressing BMP4 expression and reflects the significant indicative role in hepatocellular carcinoma pathology and diagnosis after magnetic resonance imaging assessment. Oncol Res 2019;27:301\u20139. https:\/\/doi.org\/10.3727\/096504018x15213058045841.","DOI":"10.3727\/096504018X15213058045841"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_010","doi-asserted-by":"crossref","unstructured":"Legoix, P, Bluteau, B, Bayer, J, Perret, C, Balabaud, C, Belghiti, J, et al. Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene 1999;18:4044\u20136. https:\/\/doi.org\/10.1038\/sj.onc.1202800.","DOI":"10.1038\/sj.onc.1202800"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_011","unstructured":"Wu, X, Yang, L. Signaling pathways in liver cancer. London: In: Prof Julianov, A, editors. Liver tumors. London: InTech. Available from: http:\/\/www.intechopen.com\/books\/livertumors\/signaling-pathways-in-liver-cancer."},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_012","doi-asserted-by":"crossref","unstructured":"Dalamaga, M, Christodoulatos, S. Visfatin, obesity, and cancer. Adipocytokines Energy Bal Canc 2017;12:109\u201336. https:\/\/doi.org\/10.1007\/978-3-319-41677-9_6.","DOI":"10.1007\/978-3-319-41677-9_6"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_013","doi-asserted-by":"crossref","unstructured":"Schuster, S, Penke, M, Gorski, T, Gebhardt, R, Weesiss, TS, Kiess, W, et al. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells. Biochem Biophys Res Commun 2015;458:334\u201340. https:\/\/doi.org\/10.3727\/096504018x15213058045841.","DOI":"10.1016\/j.bbrc.2015.01.111"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_014","doi-asserted-by":"crossref","unstructured":"Feitelson, M, Arzumanyan, A, Kulathinal, R, Blain, SW, Holcombe, RF, Mahajna, J, et al. Sustained proliferation in cancer: mechanisms and noel therapeutic targets. Semin Canc Biol 2015;35:S25\u201354. https:\/\/doi.org\/10.1016\/j.semcancer.2015.02.006.","DOI":"10.1016\/j.semcancer.2015.02.006"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_015","doi-asserted-by":"crossref","unstructured":"Luo, Z, Zhang, Y, Li, F, He, J, Ding, H, Yan, L, et al. Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells. Endocrine 2009;36:60\u20139. https:\/\/doi.org\/10.1007\/s12020-009-9198-7.","DOI":"10.1007\/s12020-009-9198-7"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_016","doi-asserted-by":"crossref","unstructured":"Miethe, C, Nix, H, Martin, R, Hernandez, AR, Price, RS. Silibinin reduces the impact of obesity on invasive liver cancer. J Nutr Canc 2017:1532\u20137914. https:\/\/doi.org\/10.1080\/01635581.2017.1367935.","DOI":"10.1080\/01635581.2017.1367935"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_017","doi-asserted-by":"crossref","unstructured":"Wu, R, Duan, L, Cui, F, Cao, J, Xiang, Y, Tang, Y, et al. S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1\/2 and p38 MAPK pathways. Exp Cell Res 2015;334:228\u201338. https:\/\/doi.org\/10.1016\/j.yexcr.2015.04.008.","DOI":"10.1016\/j.yexcr.2015.04.008"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_018","doi-asserted-by":"crossref","unstructured":"Guo, Y, Ma, J, Wu, L, Wang, Q, Li, X, Li, X, et al. Hyperthermia-induced NDRG2 upregulation inhibits the invasion of human hepatocellular carcinoma via suppressing ERK1\/2 signaling pathway. PloS One 2013;8:e61079. https:\/\/doi.org\/10.1371\/journal.pone.0061079.","DOI":"10.1371\/journal.pone.0061079"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_019","doi-asserted-by":"crossref","unstructured":"El-Shafey, EM, El-Naggar, GF, Al-Bedewy, MM, El-Sorogy, H. Is there A relationship between visfatin level and type 2 diabetes mellitus in obese and non obese patients? J Diabetes Metabol 2012;S11:001. https:\/\/doi.org\/10.4172\/2155-6156.S11-001.","DOI":"10.4172\/2155-6156.S11-001"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_020","doi-asserted-by":"crossref","unstructured":"Filippatosm, TD, Derdemezis, CS, Kiortsis, DN, Tselepis, AD, Elisaf, MS. J Endocrinol Invest 2007;30:323. https:\/\/doi.org\/10.1007\/bf03346300.","DOI":"10.1007\/BF03346300"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_021","doi-asserted-by":"crossref","unstructured":"Chen, M-P, Chung, F-M, Chang, D-M, Tsai, Jc, Huang, HF, Shin, SJ, et al. Elevated plasma level of visfatin\/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metabol 2006;91:295\u20139. https:\/\/doi.org\/10.1210\/jc.2005-1475.","DOI":"10.1210\/jc.2005-1475"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_022","doi-asserted-by":"crossref","unstructured":"Tolosa, L, Teresa Donato, M, G\u00f3mez-Lech\u00f3n, MJ. General cytotoxicity assessment by means of the MTT assay. In: Protocols in In Vitro hepatocyte research. New York, NY: Humana Press; 2015:333\u201348 pp.","DOI":"10.1007\/978-1-4939-2074-7_26"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_023","unstructured":"Corning. Corning BioCoat matrigel invasion chamber. Available from: https:\/\/www.corning.com\/media\/jp\/cls\/documents\/jp-literature\/applicationnotej\/Matrigel_Invasion_Chamber_6-Experimental_Procedure-2_6-Other-5_Protocol_6-Reference_EN.pdf [Accessed Feb 2018]."},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_024","unstructured":"ThermoFisher Scientific. MMP9 human ELISA kit. Available from: https:\/\/www.thermofisher.com\/order\/catalog\/product\/BMS2016-2 [Accessed Feb 2018]."},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_025","unstructured":"ThermoFisher Scientific. Pierce BCA protein assay kit. Available from: https:\/\/www.thermofisher.com\/order\/catalog\/product\/23225 [Accessed Feb 2018]."},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_026","doi-asserted-by":"crossref","unstructured":"Naim, A, Pan, Q, Baig, MS. Matrix metalloproteinases (MMPs) in liver diseases. J Clin Exp Hepatol 2017;7:367\u201372. https:\/\/doi.org\/10.1016\/j.jceh.2017.09.004.","DOI":"10.1016\/j.jceh.2017.09.004"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_027","doi-asserted-by":"crossref","unstructured":"Adya, R, Tan, BK, Punn, A, Chen, J, Randeva, HS. Visfatin induces human endothelial VEGF and MMP-2\/9 production via MAPK and PI3K\/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008;78:356\u201365. https:\/\/doi.org\/10.1093\/cvr\/cvm111.","DOI":"10.1093\/cvr\/cvm111"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_028","doi-asserted-by":"crossref","unstructured":"Nishikawa, M. Reactive oxygen species in tumor metastasis. Canc Lett 2008;266:53\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2008.02.031.","DOI":"10.1016\/j.canlet.2008.02.031"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_029","doi-asserted-by":"crossref","unstructured":"Zaidi, N, Lupien, L, Kuemmerle, NB, Kinla, WB, Swinnen, JV, Smans, K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res 2013;52:585\u20139. https:\/\/doi.org\/10.1016\/j.plipres.2013.08.005.","DOI":"10.1016\/j.plipres.2013.08.005"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_030","doi-asserted-by":"crossref","unstructured":"Miethe, C, Zamora, M, Torres, L, Raign, KG, Groll, CJ, Price, RS. Characterizing the differential physiological effects of adipocytokines visfatin and resistin in liver cancer cells. Horm Mol Biol Clin Invest 2019;38:2. https:\/\/doi.org\/10.1515\/hmbci-2018-0068.","DOI":"10.1515\/hmbci-2018-0068"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_031","doi-asserted-by":"crossref","unstructured":"Lach, H, Michalak, A. Oxidative stress as a crucial factor in liver disease. World J Gastroenterol 2014;20:8082\u201391. https:\/\/doi.org\/10.3748\/wjg.v20.i25.8082.","DOI":"10.3748\/wjg.v20.i25.8082"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_032","doi-asserted-by":"crossref","unstructured":"Keibler, M, Wasylenko, T, Kelleher, J, Iliopoulos, O, Vander Hieden, MG, Stephanopoulos, G, et al. Metabolic requirements for cancer cell proliferation. Canc Metabol 2016;4:16. https:\/\/doi.org\/10.1186\/s40170-016-0156-6.","DOI":"10.1186\/s40170-016-0156-6"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_033","doi-asserted-by":"crossref","unstructured":"Wang, Y, Gao, C, Shang, Y, Gao, J, Teng, F, Tian, W, et al. Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K\/Akt and MAPK\/ERK1\/2 signalling pathways. Gynecol Oncol 2016;143:168\u201378. https:\/\/doi.org\/10.1016\/j.ygyno.2016.07.109.","DOI":"10.1016\/j.ygyno.2016.07.109"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_034","doi-asserted-by":"crossref","unstructured":"Goetz, EM, Ghandi, M, Treacy, DJ, Wagle, N, Garraway, LA. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Canc Res 2014;74:7079\u201389. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2073.","DOI":"10.1158\/0008-5472.CAN-14-2073"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_035","doi-asserted-by":"crossref","unstructured":"Wang, Z, Li, Z, Ye, Y, Xie, L, Li, W. Oxidative stress and liver cancer: etiology and therapeutic targets. Oxid Med Cell Longev 2016;2016:789157. https:\/\/doi.org\/10.1155\/2016\/7891574.","DOI":"10.1155\/2016\/7891574"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_036","doi-asserted-by":"crossref","unstructured":"Azuma, K, Katsukawa, F, Oguchi, S, Muratat, M, Yamazaki, H, Shimada, A, et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 2003;11:997\u20131001. https:\/\/doi.org\/10.1038\/oby.2003.137.","DOI":"10.1038\/oby.2003.137"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_037","doi-asserted-by":"crossref","unstructured":"Oita, RC, Ferdinando, D, Wilson, S, Bunce, C, Mazzatti, DJ. Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt-and MAPK-independent, NF\u0138B-dependent manner. Pflueg Arch Eur J Physiol 2010;459:619\u201330. https:\/\/doi.org\/10.1007\/s00424-009-0752-1.","DOI":"10.1007\/s00424-009-0752-1"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_038","doi-asserted-by":"crossref","unstructured":"Patel, ST, Mistry, T, Brown, JE, Digby, JE, Adya, R, Desai, KM, et al. A novel role for the adipokine visfatin\/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides 2010;31:51\u20137. https:\/\/doi.org\/10.1016\/j.peptides.2009.10.001.","DOI":"10.1016\/j.peptides.2009.10.001"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_039","doi-asserted-by":"crossref","unstructured":"Sun, Y, Zhu, S, Wu, Z, Huang, Y, Liu, C, Tang, S, et al. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma. Oncotarget 2017;8:23427. https:\/\/doi.org\/10.18632\/oncotarget.15080.","DOI":"10.18632\/oncotarget.15080"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_040","doi-asserted-by":"crossref","unstructured":"Tsai, I-T, Wang, CO, Yu, TH, Lu, YC, Lin, CW, Lu, LF, et al. Circulating visfatin level is associated with hepatocellular carcinoma in chronic hepatitis B or C virus infection. Cytokine 2017;90:54\u20139. https:\/\/doi.org\/10.1016\/j.cyto.2016.10.007.","DOI":"10.1016\/j.cyto.2016.10.007"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_041","doi-asserted-by":"crossref","unstructured":"Giannelli, G, Koudelkova, P, Dituri, F, Miulits, W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol 2016;65:798\u2013808. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.007.","DOI":"10.1016\/j.jhep.2016.05.007"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_042","doi-asserted-by":"crossref","unstructured":"Swamy, SG, Kameshwar, VH, Shubha, PB, Looi, CY, Shanmugam, MK, Arfuso, F, et al. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Targeted Oncol 2017;12:1\u201310. https:\/\/doi.org\/10.1007\/s11523-016-0452-7.","DOI":"10.1007\/s11523-016-0452-7"},{"key":"2025121207243546721_j_hmbci-2021-0011_ref_043","doi-asserted-by":"crossref","unstructured":"Yan, L, Xu, F, Dai, C-L. Relationship between epithelial-to-mesenchymal transition and the inflammatory microenvironment of hepatocellular carcinoma. J Exp Clin Canc Res 2018;37:1\u201313. https:\/\/doi.org\/10.1186\/s13046-018-0887-z.","DOI":"10.1186\/s13046-018-0887-z"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0011\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0011\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:26:27Z","timestamp":1765527987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2021-0011\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,8,9]]},"published-print":{"date-parts":[[2021,12,8]]}},"alternative-id":["10.1515\/hmbci-2021-0011"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2021-0011","relation":{},"ISSN":["1868-1891"],"issn-type":[{"value":"1868-1891","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]}}}